Request Demo

Last update 08 May 2025

Quartan malaria

Last update 08 May 2025

Basic Info

Synonyms

Malaria by Plasmodium malariae, Malaria, quartan, Malariae malaria

+ [15]

Introduction

Malaria resulting from infection by Plasmodium malariae.

Drugs associated with Quartan malaria

Artemisinin/Hydroxychloroquine Sulfate

Target-

Mechanism-

Active Org.

Guangdong Xin Nanfang Qinghao Pharmaceutical Co. Ltd. [+1]

Originator Org.

Guangdong Xin Nanfang Qinghao Pharmaceutical Co. Ltd.

Active Indication

Malaria, Falciparum [+2]

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Quartan malaria

CTR20242902

/ RecruitingPhase 1

单中心、开放、剂量递增、单次给药观察青蒿素硫酸羟氯喹片在健康受试者中的耐受性及药代动力学临床试验

[Translation] A single-center, open-label, dose-escalation, single-dose clinical trial to observe the tolerability and pharmacokinetics of artemisinin sulfate hydroxychloroquine tablets in healthy subjects

1、本研究选择健康受试者为试验对象，考察健康受试者单药给予青蒿素硫酸羟氯喹片的耐受性，确定最大耐受剂量（MTD）。 2、评价青蒿素硫酸羟氯喹片单次给药在健康受试者体内的药代动力学（pharmacokinetics，PK）特征。

[Translation]

1. This study selected healthy subjects as test subjects to investigate the tolerance of artemisinin sulfate hydroxychloroquine tablets to healthy subjects and determine the maximum tolerated dose (MTD). 2. Evaluate the pharmacokinetic (PK) characteristics of artemisinin sulfate hydroxychloroquine tablets in healthy subjects after single administration.

Start Date31 Jul 2024

Sponsor / Collaborator

Guangdong Xin Nanfang Qinghao Pharmaceutical Co. Ltd.

[+1]

CTRI/2024/04/065866

/ Not yet recruitingNot ApplicableIIT

Development and evaluation of diagnostic tool for differentiating tropical fevers using an artificial intelligence approach. - nil

Start Date15 May 2024

Sponsor / Collaborator

Manipal Academy of Higher Education

CTRI/2023/01/049230

/ Not yet recruitingNot ApplicableIIT

A Prospective Observational Study of profile of Select Acute Febrile Illness cases admitted to a tertiary care hospital - Nil

Start Date01 Feb 2023

Sponsor / Collaborator-

100 Clinical Results associated with Quartan malaria

100 Translational Medicine associated with Quartan malaria

0 Patents (Medical) associated with Quartan malaria

954

Literatures (Medical) associated with Quartan malaria

31 Dec 2025·Emerging Microbes & Infections

Unprecedented large outbreak of Plasmodium malariae malaria in Vietnam: Epidemiological and clinical perspectives

Article

Author: Trung, Nguyen Kim ; Na, Byoung-Kuk ; Quan, Pham Minh ; Lê, Hương Giang ; Võ, Tuấn Cường ; Van, Tran Thi Hue ; Dung, Nguyen Cong Trung ; Nguyen, Do Van ; Nguyễn, Đăng Thùy Dương ; Vinh, Le Duc ; Quang, Nguyen Xuan ; Nguyễn, Thu Hằng ; Nhien, Nguyen Thanh Thuy ; Quang, Huynh Hong ; Kang, Jung-Mi ; Tam, Le Thanh ; Khanh, Chau Van

Plasmodium malariae, a causative agent of quartan malaria, is prevalent across tropical and subtropical regions, but global cases have been usually very rare and sporadic. However, a significant outbreak of quartan malaria caused by P. malariae occurred in Khanh Vinh District, Khanh Hoa Province, Vietnam in 2023 and the outbreak persists. In this report, we present the epidemiological and clinical characteristics of this unprecedented outbreak of quartan malaria in Vietnam.

01 Apr 2025·Microbiology Spectrum

Differential ex vivo susceptibility of Plasmodium malariae and Plasmodium falciparum clinical isolates from Ghana and Mali to current and lead discovery candidate antimalarial drugs

Article

Author: Diakite, Ousmaila ; Sogore, Fanta ; Campo, Brice ; Dembele, Laurent ; Chirawurah, Jersley D. ; Maiga, Mohamed ; Ansah, Felix ; Maiga, Fatoumata O. ; Soulama, Alamissa ; Danwonno, Harry A. ; Amenga-Etego, Lucas N. ; Aniweh, Yaw ; Djimde, Abdoulaye A. ; Awandare, Gordon A.

ABSTRACT Non-falciparum species causing malaria in humans are considered neglected in the fight toward malaria elimination. Recent data highlight the increasing contribution of Plasmodium malariae to malaria morbidity and mortality. In this study, the susceptibility of P. malariae and Plasmodium falciparum to current antimalarial drugs was compared to advanced lead candidate drugs using field isolates. The blood samples were collected from the Central region of Ghana and Faladje and Kati in Mali. Following this, an ex vivo drug efficacy assay was conducted by screening mono-infected isolates against a panel of antimalarials. In Ghana, the susceptibility of the two species to most of the current antimalarial drugs was comparable, except for artemether, sulfadoxine, and atovaquone, for which the drugs were less potent against P. malariae than P. falciparum (7.12 vs 2.15 nM, 25.72 vs 7.86 nM, and 10.38 vs 2.51 nM, respectively). In Mali, quinine was significantly more potent against P. malariae than P. falciparum (18.35 and 26.84 nM), and tafenoquine was less potent against P. malariae than P. falciparum (5.50 and 2.85 nM). Among the candidate drugs, except INE963, whose inhibitory potency was comparable between both species, the other compounds significantly inhibited P. malariae more than P. falciparum . The data showed that current drugs investigated against the isolates from Ghana may be suitable for curing P. malariae infections. However, in Mali, chloroquine resistance appeared to have affected the suitability of quinine-based compounds for non-falciparum malaria treatment. Therefore, additional studies are required to establish the efficacy of artemether-lumefantrine for the treatment of P. malariae infections. IMPORTANCE One major hurdle to research in the community is our inability to have continuous culture for parasites such as Plasmodium malariae and Plasmodium ovale . These two are common in the West African region and co-occur with Plasmodium falciparum in driving both clinical or asymptomatic infections as either mono-infections or mixed infections. This manuscript is a buildup of our efforts at using ex vivo methods to study the susceptibility of P. malariae and P. falciparum to conventional and lead compounds, comparing the isolates from Ghana and Mali. This is necessary to facilitate drug discovery efforts in combating malaria holistically. The community will greatly see this work as a step in the right direction, stimulating more research into these other parasites causing malaria.

01 Mar 2025·Travel Medicine and Infectious Disease

A case of imported Plasmodium malariae infection after treated Plasmodium falciparum malaria: Possible explanations and a review of the literature

Letter

Author: Boccolini, Daniela ; Zammarchi, Lorenzo ; Lanari, Alessandro ; Severini, Carlo ; Richter, Joachim ; Rossolini, Gian Maria ; Aiello, Andrea ; L'Episcopia, Mariangela ; Paggi, Riccardo ; Bartoloni, Alessandro ; Lapini, Manuela ; Malcontenti, Costanza ; Nencioni, Cesira

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Quartan malaria

Basic Info

Related

Analysis